Clinical Trial Update: Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating post-transplant autologous cytokine-induced killer (CIK) cells in high-risk hematologic malignancies has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Multiple Myeloma

Drugs mentioned

• Cytokine-induced killer (CIK) cells (cytokine-induced killer cells)

Snippet

Sponsor: Sally Arai | Conditions: Leukemia, Multiple Myeloma | Phase 1 | Status: COMPLETED